Therapy News and Research

RSS

Research to identify new potential targets for cancer therapy

In 2012, about 8.2 million people died of cancer making the disease a major cause of death worldwide. According to the WHO World Cancer Report 2014, this figure is expected to rise within the next two decades.

11 Jun 2014

EU-funded project aims to identify potential new targets for cancer therapy

Targeted therapies have revolutionised the treatment of cancer since they were first introduced. Amongst the first medications approved in Europe, was the breast cancer drug Herceptin, which was approved in 2000. Then, the drug Glivec, was initially introduced to treat a certain form of leukaemia, and approved in 2001. Targeted therapies specifically inhibit molecules within so-called signalling pathways that usually control cell growth, death and differentiation. If they are altered, for example falsely inactivated or activated, the cells may start growing in an uncontrolled manner.

11 Jun 2014

New guidelines aim to improve delivery of prostate cancer survivorship care

New American Cancer Society Prostate Cancer Survivorship Care guidelines released today outline posttreatment clinical follow-up care for the myriad of long-term and late effects an estimated 2.8 million prostate cancer survivors in the United States may face.

11 Jun 2014

Children of parents with BD are at greater risk of developing psychiatric disorders

Bipolar disorder (BD) is among the 10 most burdensome medical conditions, according to the World Health Organization. The disorder is known for its dramatic highs of extreme euphoria, racing thoughts and decreased need for sleep, as well as its profound lows of sadness and despair.

11 Jun 2014

Mirna enrolls first patient in hematological malignancy cohort of MRX34 Phase 1 clinical trial

Mirna Therapeutics, Inc., a clinical-stage biopharmaceutical company pioneering microRNA-based Replacement Therapy to treat cancer, today announced the enrollment of the first patient in the hematological malignancy cohort of its ongoing Phase 1 clinical trial of MRX34, the company's lead product candidate and first microRNA mimic in human clinical trials in oncology.

11 Jun 2014

Treato releases third version of flagship patient intelligence platform

Treato, the world's most comprehensive source of real-time patient voice insights, today announced the release of version 3 of its flagship patient intelligence platform.

10 Jun 2014

Alkermes initiates FORWARD-3 and FORWARD-4 efficacy studies in pivotal clinical program for ALKS 5461

Alkermes plc today announced the initiation of FORWARD-3 and FORWARD-4, two of the three planned phase 3 core efficacy studies in the pivotal clinical program for ALKS 5461, a once-daily, oral investigational medicine with a novel mechanism of action for the adjunctive treatment of major depressive disorder (MDD).

10 Jun 2014

Alnylam announces new pre-clinical results with DC for ALN-CC5 to treat complement-mediated diseases

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today new pre-clinical results with its Development Candidate (DC) for ALN-CC5, a subcutaneously administered investigational RNAi therapeutic targeting complement component C5 in development for the treatment of complement-mediated diseases.

10 Jun 2014

$arGEN-X partner with LLS to develop ARGX-110 for patients with refractory WM$

arGEN-X partner with LLS to develop ARGX-110 for patients with refractory WM

arGEN-X, a clinical stage biopharmaceutical company focused on creating and developing differentiated therapeutic antibodies for the treatment of cancer and severe autoimmune diseases, today announced it has entered into a partnership with The Leukemia & Lymphoma Society (LLS) in which both parties will contribute to the funding of a Phase 2 clinical study of the Company's lead candidate, ARGX-110, in patients with refractory Waldenström's macroglobulinemia (WM).

10 Jun 2014

electroCore's non-invasive vagus nerve stimulation therapy reduces cluster headache attacks

In a multi-center, randomized, trial across Europe, electroCore's non-invasive vagus nerve stimulation (nVNS) therapy was found to meet its primary endpoint of statistical significance in reducing the number of cluster headache attacks when compared with the standard of care.

10 Jun 2014

Inovio evaluates responses of immunotherapy product in treating HPV linked head and neck cancer

Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) today announced it has initiated a phase I/IIa clinical trial to evaluate safety, immunogenicity and clinical responses of its immunotherapy product, INO-3112, in treating human papillomavirus (HPV)- associated head and neck cancer.

10 Jun 2014

Synthetic, Enterome partner to study effects of beta-lactam antibiotics on gastrointestinal microflora

Synthetic Biologics, Inc., a developer of novel anti-infective biologic and drug candidates targeting specific pathogens that cause serious infections and diseases, and Enterome Bioscience SA, a pioneer in the development of innovative disease management solutions based on a deep understanding of the gut microbiome, today announced that they have entered into an agreement to conduct metagenomic research on the effects of beta-lactam antibiotics on the gastrointestinal microflora (microbiome) of human patients.

10 Jun 2014

Groundbreaking molecular imaging agent developed to trace advanced prostate cancer

Anti-androgen hormonal therapy, also called chemical castration, can be an important defense against further disease progression for patients with prostate cancer that has traveled and grown in other areas, or metastasized-but some cases simply do not respond to this treatment.

10 Jun 2014

Researchers reveal mysterious behavior of individual cells using radioluminescence microscopy

With a new molecular imaging system powerful enough to peer down to 20-micrometer resolution, researchers can now use radioluminescence to examine the characteristics of single, unconnected cells. The result is a fascinating picture of diversity among cells previously assumed to behave the same, revealed researchers at the Society of Nuclear Medicine and Molecular Imaging's 2014 Annual Meeting.

10 Jun 2014

MD Anderson study shows that needle biopsy underused in breast cancer patients

Needle biopsy, the standard of care radiological procedure for diagnosing breast cancer, is underused with too many patients undergoing the more invasive, excisional biopsy to detect their disease, according to research from The University of Texas MD Anderson Cancer Center.

10 Jun 2014

Protein may be key to maintaining health of aging blood stem cells

A protein may be the key to maintaining the health of aging blood stem cells, according to work by researchers at the Icahn School of Medicine at Mount Sinai recently published online in Stem Cell Reports.

10 Jun 2014

Combined chemo and radionuclide therapy stops neuroendocrine tumors

Advanced cancer of the neuroendocrine system can lead to dismal prognoses, but a novel therapy is packing a punch by uniting powerful radionuclide treatment and chemotherapy drugs, revealed researchers at the Society of Nuclear Medicine and Molecular Imaging's 2014 Annual Meeting.

10 Jun 2014

Combination of novel molecular imaging techniques can help predict spread of cancer, patient survival

A simple noninvasive blood test matched with state-of-the-art molecular imaging of individual cells could help oncologists understand their patients' chances of survival, say researchers at the Society of Nuclear Medicine and Molecular Imaging's 2014 Annual Meeting.

10 Jun 2014

Antibody-based molecular imaging agent offers hope for novel breast cancer treatments

For years researchers have been developing molecular imaging techniques that visualize hormonally active breast cancer cells-specifically those testing positive for human epidermal growth factor receptor 2 (HER2).

10 Jun 2014

FDA accepts Pharmacyclics' IMBRUVICA sNDA for review

Pharmacyclics, Inc. today announced that the U.S. Food and Drug Administration has accepted for filing its supplemental New Drug Application (sNDA) to support the review of IMBRUVICA (ibrutinib) in the treatment of patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) who have received at least one prior therapy for a full approval.

9 Jun 2014

Therapy News and Research

Research to identify new potential targets for cancer therapy

EU-funded project aims to identify potential new targets for cancer therapy

New guidelines aim to improve delivery of prostate cancer survivorship care

Children of parents with BD are at greater risk of developing psychiatric disorders

Mirna enrolls first patient in hematological malignancy cohort of MRX34 Phase 1 clinical trial

Treato releases third version of flagship patient intelligence platform

Alkermes initiates FORWARD-3 and FORWARD-4 efficacy studies in pivotal clinical program for ALKS 5461

Alnylam announces new pre-clinical results with DC for ALN-CC5 to treat complement-mediated diseases

arGEN-X partner with LLS to develop ARGX-110 for patients with refractory WM

electroCore's non-invasive vagus nerve stimulation therapy reduces cluster headache attacks

Inovio evaluates responses of immunotherapy product in treating HPV linked head and neck cancer

Synthetic, Enterome partner to study effects of beta-lactam antibiotics on gastrointestinal microflora

Groundbreaking molecular imaging agent developed to trace advanced prostate cancer

Researchers reveal mysterious behavior of individual cells using radioluminescence microscopy

MD Anderson study shows that needle biopsy underused in breast cancer patients

Protein may be key to maintaining health of aging blood stem cells

Combined chemo and radionuclide therapy stops neuroendocrine tumors

Combination of novel molecular imaging techniques can help predict spread of cancer, patient survival

Antibody-based molecular imaging agent offers hope for novel breast cancer treatments

FDA accepts Pharmacyclics' IMBRUVICA sNDA for review

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News